A comparative analysis for anti-viral drugs : Their efficiency against SARS-CoV-2

Copyright © 2020 Elsevier B.V. All rights reserved..

Coronavirus, known as the coronavirus pandemic, is continuing its spread across the world, with over 42 million confirmed cases in 189 countries and more than 1.15 million deaths. Although, scientists focus on the finding novel drugs and vaccine for SARS-CoV-2, there is no certain treatment for it. Antiviral drugs such as; oseltamivir, favipiravir, umifenovir, lopinavir, remdesivir, hydroxychloroquine, chloroquine, azithromycin, ascorbic acid, corticosteroids, are mostly used for patients. They prevent cytokine storm that is the main reason of deaths related to SARS-CoV-2. In addition, anti-inflammatory agents have critical roles to inhibit the lung injury and multisystem organ dysfunction. The combination with anti-viral drugs with other drugs displays high synergistic effects. In the present study, the drugs used for Covid-19 are analyzed and compare the efficiency for the Covid-19 patients from the different continents including USA, South Korea, Italy, Spain, Germany, Russia, Brazil, Turkey, and China. Nowadays, all countries tried to find vaccine and new drug candidates for SARS-CoV-2, but anti-viral drugs may be the best candidates for the treatment of Covid-19 before finding novel anti-Covid drug.

Media Type:

Electronic Article

Year of Publication:

2021

Contained In:

International immunopharmacology - Vol. 90 (2021), p. 107232

Language:

English

Contributors:

Kivrak, Arif
Ulaş, Berdan
Kivrak, Hilal

Links:

Volltext

Keywords:

*SARS-CoV-2
Anti-viral
Antiviral Agents
COVID-19
Comparative Study
Covid-19
Drug
Favipiravir
Humans
Journal Article
Remdesevir
Review
SARS-CoV-2
Treatment Outcome

Notes:

Date Completed 22.01.2021

Date Revised 27.01.2021

published: Print-Electronic

Citation Status MEDLINE

Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Physical Description:

Online-Ressource

doi:

10.1016/j.intimp.2020.107232

PMID:

33290969

PPN (Catalogue-ID):

NLM319570738